Praxis Precision Medicines Inc (PRAX): Enterprise Value to EBITDA Ratio
The EV/EBITDA history of Praxis Precision Medicines allows for an assessment of the company's dependence on ulixacaltamide test results and its cash reserves. Currently, 0.00 reflects the latest level of this metric. Current epilepsy treatments are undergoing testing and have not yet reached the sales stage. Meanwhile, the efficacy of the therapy is guaranteed by strict adherence to temperature controls during drug transportation.
Comprehensive metric breakdowns and analytics for praxismedicines.com (PRAX)
- current price and projected stock value:
- stock exchange capitalization data:
- business book valuation details:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Praxis Precision Medicines|PRAX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Praxis Precision Medicines, Inc.|PRAX - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Praxis Corp|PRAX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Praxis Precision Medicines|Quick Ratio praxismedicines.com
- financial results and valuation multiples details:
PRAX - Net Income|Projected Future Earnings Praxis Precision Medicines|PRAX - Business Payback Period|Future Price to Earnings Praxis Precision Medicines|PRAX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Praxis Corp|PRAX - Operating income before deduction of amortization|Earnings per share for the last twelve months Praxis Precision Medicines|PRAX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months praxismedicines.com|PRAX - Earnings per share growth this year|Expected earnings per share growth for next year Praxis Precision Medicines
Fundamental valuation:PRAX (Praxis Medicines)
For Praxis Precision Medicines (PRAX), whose success depends on the clinical trial outcomes of the ulixacaltamide molecule, the valuation of the business relative to EBITDA is critically important. This ratio compares the enterprise value (EV) with the company's ability to generate cash flow, neutralizing the impact of debt loads and tax regimes. A decline in the business valuation via EV/EBITDA may signal either an undervalued asset or a shortening of the financial runway.
Key competitors
EV/EBITDA Multiple BIIB (Biogen Corp)|EV/EBITDA Multiple Neurocrine Corp NBIX|RGC: Enterprise Value to EBITDA Ratio|AXSM (axsome.com) - Enterprise Value to Operating Income Before Depreciation|ACAD: EV/EBITDA Multiple|XENE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Supernus Corp (SUPN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN (Biohaven Ltd) - Company Value to Operating Income Before Depreciation Ratio|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|AVXL: EV/EBITDA Multiple|Company Value to EBITDA ceribell.com (CBLL)|PRTA (Prothena Corporation plc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Alector Therapeutics (ALEC)|EV/EBITDA Multiple ANNX|Total Company Value to Operating Income Before Depreciation Ratio omeros.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|Total Company Value to Operating Income Before Depreciation Ratio acimmune.com (ACIU)|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Neumora NMRA|Scilex Holding Co. (SCLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Tevogen Bio Inc. (TVGN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alpha Cognition Inc|Enterprise Value to Operating Income Before Depreciation CGTX (cogrx.com)|Enterprise Value to EBITDA Ratio IKT (Inhibikase Therapeutics, Inc.)|SAVA (Cassava Sciences Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assertio ASRT|COYA - Enterprise Value to EBITDA Ratio|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Ovid Therapeutics Inc.|ABOS: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CRVO|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|Clene Nanomedicine (CLNN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PEPG|Enterprise Value to EBITDA Ratio jupiterneurosciences.com JUNS|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Annovis Bio Inc (ANVS)|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MetaVia, Inc. (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Business Value to Operating Income Before Depreciation NEUP|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|ATHA - EV/EBITDA Multiple|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation ALZN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation PTIX (Protagenic)|EV/EBITDA Multiple KTTA|CRGT - Company Value to EBITDA|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple BrainStorm Cell Therapeutics Inc. BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (chromocell.com)|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Intra-Cellular Therapies, Inc. (ITCI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Marinus Pharma - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN: Enterprise Value to EBITDA Ratio|VIGL (Vigil Neuroscience) - Enterprise Value to Operating Income Before Depreciation|WENA: EV/EBITDA Multiple|CERE - Total Company Value to Operating Income Before Depreciation Ratio
